You are viewing: China Leukapheresis Market analysis
Part of: Leukapheresis Market (Global)

The China Leukapheresis Market was valued at $5.43 Million in 2026 and projected to reach to $9.17 Million by 2031, representing a compound annual growth rate of 11.1%. China's leukapheresis market is positioned for sustained growth through 2031, with the market expanding from USD 5.43 million in 2026 to USD 9.17 million by 2031.

China Leukapheresis Market (2026-2031) : Size and Share
logo-mobile
CAGR of
cagr-Chart
USD Million
MARKET SNAPSHOT
Market Size in USD 26.32 MN
Market Forecast in
CAGR
Forecast Period
Units Considered Value (USD MN)

China Leukapheresis Market Trends and Insights

  • This represents a compound annual growth rate (CAGR) of 11.1%, significantly outpacing global averages.
  • China's expanding healthcare infrastructure, rising prevalence of hematologic malignancies, and increasing adoption of advanced cell therapy technologies are driving demand for leukapheresis procedures across the country. The leukapheresis market in China is benefiting from enhanced patient access to CAR-T cell therapies and other cellular immunotherapies, which require efficient leukocyte collection.
  • China's growing investment in biotechnology and regenerative medicine, combined with improving reimbursement policies, is accelerating market penetration.
  • Between 2026 and 2031, China is expected to solidify its position as a key regional market, supported by rising treatment volumes and technological innovation in apheresis equipment and consumables..

Key Market Statistics

  • CAGR (2026-2031) 11.1% CAGR
  • Market Size, 2026 ~USD 5.43 Million
  • Forecast, 2031 ~USD 9.17 Million
  • Country China

China Leukapheresis Market Overview

Rapid Market Expansion :

China's leukapheresis market is growing at 11.1% CAGR, significantly outpacing the global rate of 8.9%, driven by increasing healthcare investments and rising demand for advanced hematologic treatments.

Rising Hematologic Malignancy Prevalence :

Growing incidence of leukemia and other blood cancers in China is fueling demand for leukapheresis procedures, supported by improved diagnostic capabilities and greater disease awareness among healthcare providers.

Healthcare Infrastructure Development :

China's expanding hospital networks and modernization of medical facilities are enabling wider adoption of leukapheresis technology, particularly in tier-1 and tier-2 cities with advanced oncology centers.

Cell Therapy Adoption Growth :

Increasing adoption of CAR-T cell therapies and other advanced cellular treatments in China is driving demand for leukapheresis as a critical component in cell collection and processing workflows.

China Leukapheresis Market Dynamics

  • This robust trajectory is underpinned by China's commitment to advancing oncology care, increasing healthcare spending, and the rising prevalence of hematologic malignancies across the population.
  • Government initiatives supporting cell therapy development and cancer treatment accessibility are accelerating market penetration. The competitive landscape in China is intensifying as both domestic manufacturers and international players establish presence in the market.
  • Investment in R&D for improved leukapheresis technologies, coupled with growing clinical adoption in major medical centers, will continue to drive market expansion.
  • Regulatory support for advanced medical devices and increasing reimbursement coverage for cell therapy procedures are expected to further accelerate market growth through the forecast period..

Related Ecosystem

Key Takeaways

  • China's leukapheresis market is projected to grow from USD 5.43 million in 2026 to USD 9.17 million in 2031, representing an 11.1% CAGR.
  • China's expanding CAR-T cell therapy adoption and cellular immunotherapy programs are primary drivers of leukapheresis demand.
  • China's improving healthcare infrastructure and reimbursement policies are accelerating market accessibility and procedure volumes.
  • China is positioned as a high-growth regional market, outpacing global leukapheresis market expansion rates through 2031.

Leukapheresis Market Report Scope

Report Metric Details
Base Year 2026
Fastest Growing Segment MULTIPLE MYELOMA (Indication)
Forecast Period 2026–2031
Growth Rate CAGR of 8.9% from 2026 to 2031
Largest Segment ACUTE LYMPHOCYTIC LEUKEMIA (Indication)
Market Size Base Year (Billions) ~USD 0.09 (2026)
Revenue Forecast (Billions) ~USD 0.14 (2031)
Segments Covered Product Type, Product Type 2024–2031, Type, Application, End User, Indication, Leukopak Type

China Leukapheresis Market Report Segmentation

7 segment dimensions are covered across the global market.

By Product Type

  • Devices
  • Disposables
  • Leukapheresis Devices
  • Leukapheresis Disposables

By Product Type 2024–2031

  • Collection Kits & Accessories
  • Filters & Membrane Consumables
  • Tubing Sets & Collection Bag

By Type

  • Australia
  • Belgium
  • Brazil
  • Canada
  • Centrifugal Devices
  • China
  • Diseased Leukopaks
  • France
  • Germany
  • India
  • Isolated Pbmcs
  • Italy
  • Japan
  • Kingdom Of Saudi Arabia (Ksa)
  • Membrane Separators
  • Mexico
  • Mobilized Leukopaks
  • Netherlands
  • New Zealand
  • Non-Mobilized Leukopaks
  • Poland
  • Rest Of Asia Pacific
  • Rest Of Europe
  • Rest Of GCC Countries
  • Rest Of Latin America
  • Rest Of Middle East & Africa
  • South Korea
  • Spain
  • Switzerland
  • Thailand
  • UK
  • United Arab Emirates (UAE)
  • US

By Application

  • Research Applications
  • Therapeutic Applications

By End User

  • Academic & Research Institutes
  • Blood Component Providers & Blood Centers
  • Contract Research Organizations
  • Hospitals & Transfusion Centers
  • Pharmaceutical & Biotechnology Companies

By Indication

  • Acute Lymphocytic Leukemia
  • Chronic Lymphocytic Leukemia
  • Hepatocellular Carcinoma
  • Multiple Myeloma
  • Non-Hodgkin’S Lymphoma
  • Other Indications
  • Pancreatic Cancer

By Leukopak Type

  • Diseased Leukopaks
  • Isolated Pbmcs
  • Mobilized Leukopaks
  • Non-Mobilized Leukopaks

CHINA: LEUKOPAKS MARKET, BY END USER, 2024–2031

Segment20242025202620272028202920302031CAGR (%)
ACADEMIC & RESEARCH INSTITUTES13.1115.0517.3119.9623.0626.6930.9736.0115.8
CONTRACT RESEARCH ORGANIZATIONS1.461.641.842.082.352.653.013.4213.2
PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES4.935.746.77.849.1910.7912.714.9817.5
TOTAL19.522.4325.8629.8834.5940.1446.6854.4116

CHINA: LEUKAPHERESIS MARKET, BY END USER, 2024–2031

Segment20242025202620272028202920302031CAGR (%)
ACADEMIC & RESEARCH INSTITUTES0.810.890.991.091.211.341.481.6410.7
BLOOD COMPONENT PROVIDERS & BLOOD CENTERS2.422.713.033.43.824.294.825.4212.3
HOSPITALS & TRANSFUSION CENTERS1.812.012.242.52.783.113.473.8811.6
PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES0.50.540.60.650.710.780.850.949.5
TOTAL5.546.166.867.648.529.5110.6311.8811.6

Target Audience

  • Medical Device Manufacturers : Manufacturers of leukapheresis equipment and cell processing systems need China-specific market data to assess market opportunity, plan product launches, and develop localized go-to-market strategies in this high-growth region.
  • Pharmaceutical & Biotech Companies : Companies developing CAR-T and cell therapies require detailed China market insights to understand demand for leukapheresis services, plan clinical trial logistics, and forecast commercial adoption rates for cell-based treatments.
  • Healthcare Investors & PE Firms : Investment professionals evaluating opportunities in China's healthcare sector need validated market sizing and growth projections to assess investment returns, identify acquisition targets, and evaluate portfolio companies in oncology and cell therapy.
  • Hospital & Clinical Center Operators : Healthcare facility administrators and oncology center directors need market intelligence to justify capital investments in leukapheresis infrastructure, plan service expansion, and benchmark against regional growth trends.
  • Market Research & Consulting Firms : Research organizations and consultants serving healthcare clients require granular China market data to support client advisory work, competitive analysis, and strategic recommendations in the leukapheresis and cell therapy sectors.

Key Companies in the China Leukapheresis Market

CompanyHQOwnershipStrongest segments
MAXCYTE, INCUnited StatesPublic CompanyExPERT instruments (ATx, STx, GTx, VLx),Disposable processing assemblies (PAs) and consumables,Licensing and technology access fees,

MAXCYTE, INC

MaxCyte, Inc. is a United States-based biotechnology company founded in 1998 that specializes in cell engineering technologies. As a publicly traded company, MaxCyte operates with 91 employees and develops innovative solutions for cell-based therapies and research applications.

Reasons to Buy this Report

  • Market Size & Growth Validation : Obtain precise market valuation for China (USD 5.43M in 2026, USD 9.17M in 2031) with verified 11.1% CAGR to support investment decisions, business planning, and competitive positioning in this high-growth market.
  • China-Specific Growth Drivers : Understand unique factors propelling China's leukapheresis market ahead of global averages, including healthcare infrastructure expansion, rising disease prevalence, and government support for advanced cell therapies.
  • Competitive Intelligence : Identify market opportunities and competitive dynamics specific to China's leukapheresis landscape, enabling strategic market entry, partnership development, and product positioning strategies tailored to local conditions.
  • Regulatory & Reimbursement Insights : Access China-specific regulatory environment and reimbursement trends affecting leukapheresis adoption, critical for understanding market barriers, pricing strategies, and healthcare system integration requirements.
  • Forecast-Driven Strategy : Leverage 5-year market projections through 2031 to develop long-term business strategies, resource allocation plans, and revenue forecasts aligned with China's accelerating leukapheresis market trajectory.

Frequently asked questions

What is the current size of China's leukapheresis market?

China's leukapheresis market was valued at USD 5.43 million in 2026 and is expected to reach USD 9.17 million by 2031.

What is the projected growth rate for leukapheresis in China?

China's leukapheresis market is projected to grow at a compound annual growth rate (CAGR) of 11.1% from 2026 to 2031.

What factors are driving leukapheresis demand in China?

Key drivers include rising adoption of CAR-T cell therapies, expanding healthcare infrastructure, increasing hematologic malignancy prevalence, and improving reimbursement policies in China.

How does China's leukapheresis market compare to global growth?

China's leukapheresis market is growing at 11.1% CAGR, significantly outpacing the global market CAGR of 8.9% through 2031.

Which therapies are driving leukapheresis procedures in China?

CAR-T cell therapies and other cellular immunotherapies are the primary drivers of leukapheresis procedure demand in China.

RESEARCH METHODOLOGY

This study extensively used both primary and secondary sources. The research involved studying various factors affecting the industry to identify segmentation types, industry trends, key players, competitive landscape, key market dynamics, and key player strategies.

Secondary Research

This research study involved the usage of comprehensive secondary sources, directories, databases such as Bloomberg Business, Factiva, and Dun & Bradstreet; white papers; annual reports; company house documents; investor presentations; and SEC filings of companies. Secondary research was used to identify and collect information useful for an extensive, technical, market-oriented, and commercial study of the leukapheresis market. It was also used to identify key players in the market and classify and segment the industry based on trends to the most detailed level. Additionally, significant developments related to market and technology perspectives were noted. A database of the primary industry leaders was also created using secondary research.

Primary Research

In the primary research process, various sources from both the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. Primary sources from the supply side include project/sales/marketing/business development managers, presidents, CEOs, vice presidents, chairpersons, chief operating officers, chief strategy officers, directors, chief information officers, and chief medical information officers related to the leukapheresis market. Primary sources from the demand side include healthcare professionals from blood component providers & blood centers, academic & research institutes, pharmaceutical & biotechnology companies, and hospitals & transfusion centers.

A breakdown of the primary respondents is provided below:

BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE PARTICIPANTS, BY COMPANY TYPE, DESIGNATION, AND REGION

Leukapheresis Market
Size, and Share

Note 1: C-level executives include CEOs, COOs, CTOs, and VPs.
Note 2: Other designations include sales, marketing, and product managers.

Note 3: Tiers are defined based on a company’s total revenue. As of 2024: Tier 1 = >USD 1 billion, Tier 2 = USD 500 million to USD 1 billion, and Tier 3 = <USD 500 million

To know about the assumptions considered for the study, download the pdf brochure

Market Size Estimation

The total size of the leukapheresis market was determined after data triangulation from three approaches, as mentioned below. After each approach, the weighted average of the three approaches was taken based on the level of assumptions used in each approach.

Leukapheresis Market Top Down and Bottom Up Approach

Data Triangulation

After arriving at the market size, the total market was divided into several segments and subsegments. Data triangulation and market breakdown procedures were employed wherever applicable to complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments.

Market Definition

Leukapheresis is the process of separating white blood cells from the whole blood. Therapeutic leukapheresis procedures are used to treat hyperleukocytic leukemia, including acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), multiple myeloma, and non-Hodgkin’s lymphoma.

Leukopaks are enriched leukapheresis products that contain mononuclear leukocytes (lymphocytes and monocytes) and are used to develop cell-based therapeutics

Key Stakeholders

  • Apheresis device manufacturers and distributors
  • Leukapheresis product manufacturers and distributors
  • Leukopak manufacturers and distributors
  • Pharmaceutical and biotechnology companies
  • Healthcare service providers (including hospitals and transfusion centers)
  • Cancer treatment centers
  • Blood component providers & blood centers
  • Contract research organizations (CROS)
  • Academic and research institutes
  • Government associations
  • Market research and consulting firms
  • Venture capitalists and investors

Report Objectives

  • To define, describe, segment, and forecast the leukapheresis market by type, application, end user, and region, and the leukopaks market, by type, indication, end user, and region
  • To provide detailed information about the factors influencing market growth (such as drivers, restraints, opportunities, and challenges)
  • To analyze micromarkets with respect to individual growth trends, prospects, and contributions to the overall leukapheresis market
  • To analyze market opportunities for stakeholders and provide details of the competitive landscape for key players
  • To forecast the size of the leukapheresis market in five main regions (along with their respective key countries), namely, North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa
  • To profile the key players in the leukapheresis market and comprehensively analyze their core competencies and market share
  • To track and analyze competitive developments such as acquisitions, product launches, expansions, collaborations, agreements, and partnerships

Available customizations:

With the given market data, MarketsandMarkets offers customizations to meet your company’s specific needs. The following customization options are available for the report:
  • Company Information

Detailed analysis and profiling of additional market players (up to 5)

  • Geographic Analysis

Further breakdown of the Rest of Europe leukapheresis market into Austria, Finland, and other countries

Further breakdown of the Rest of Latin America leukapheresis market into Colombia, Chile, and other countries

  • Competitive Landscape Assessment

Market share analysis for North America and Europe, which provides market shares of the top 3–5 key players in the leukapheresis market

Competitive leadership mapping for established players in the US

 

Get the Full Leukapheresis Market Report

Full forecast, segment splits, and company analysis for all Leukapheresis Market.

Need a Tailored Report?

Customize this report to your needs

Get 10% FREE Customization

Customize This Report
Fact checked
DMCA.com Protection Status